Top

Published in:

01-04-2014 | Original Article

Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture

Authors: Robert M. Starke, Daniel M. S. Raper, Dale Ding, Nohra Chalouhi, Gary K. Owens, David M. Hasan, Ricky Medel, Aaron S. Dumont

Published in: Translational Stroke Research | Issue 2/2014

Abstract

Inflammation is a critical process behind cerebral aneurysm formation and rupture. Tumor necrosis factor alpha (TNF-α) is a key immune modulator that has been implicated in cerebral aneurysm pathophysiology. This may occur through TNF-α-mediated endothelial injury, smooth muscle cell phenotypic modulation, recruitment of macrophages, activation of chemotactic cytokines, upregulation of matrix remodeling genes, production of free radicals leading to oxidative stress, and ultimately cellular apoptosis. Recent studies have indicated that TNF-α may be a potential target for the development of novel medical therapies, but additional experimental data is needed to clarify the intricacies of TNF-α activation and its critical downstream targets in cerebral aneurysms. This review provides an update on the mechanisms underlying TNF-α-induced molecular modulation in cerebral aneurysms.

Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2):99–103.PubMedCrossRef

Komotar RJ, Zacharia BE, Mocco J, Connolly Jr ES. Controversies in the surgical treatment of ruptured intracranial aneurysms: the First Annual J. Lawrence Pool Memorial Research Symposium—controversies in the management of cerebral aneurysms. Neurosurgery. 2008;62(2):396–407.PubMedCrossRef

van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–18.PubMedCrossRef

Kassell NF, Torner JC. The International Cooperative Study on Timing of Aneurysm Surgery—an update. Stroke. 1984;15(3):566–70.PubMedCrossRef

Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1):28–40.PubMedCrossRef

Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, et al. Risk of harboring an unruptured intracranial aneurysm. Stroke. 1998;29(2):359–62.PubMedCrossRef

Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42. doi:10.1016/S1474-4422(09)70126-7.PubMedCrossRef

Rosenorn J, Eskesen V, Schmidt K, Espersen JO, Haase J, Harmsen A, et al. Clinical features and outcome in 1076 patients with ruptured intracranial saccular aneurysms: a prospective consecutive study. Br J Neurosurg. 1987;1(1):33–45.PubMedCrossRef

Saveland H, Sonesson B, Ljunggren B, Brandt L, Uski T, Zygmunt S, et al. Outcome evaluation following subarachnoid hemorrhage. J Neurosurg. 1986;64(2):191–6.PubMedCrossRef

10.

Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488):809–17. doi:10.1016/S0140-6736(05)67214-5.PubMedCrossRef

11.

Wiebers DO, Whisnant JP, Huston 3rd J, Meissner I, Brown Jr RD, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.PubMedCrossRef

12.

Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9):1659–76. doi:10.1038/jcbfm.2012.84.PubMedCentralPubMedCrossRef

13.

Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127(3):295–314. doi:10.1016/j.pharmthera.2010.05.002.PubMedCrossRef

14.

Kosierkiewicz TA, Factor SM, Dickson DW. Immunocytochemical studies of atherosclerotic lesions of cerebral berry aneurysms. J Neuropathol Exp Neurol. 1994;53(4):399–406.PubMedCrossRef

15.

Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65. doi:10.1038/sj.cdd.4401189.PubMedCrossRef

16.

Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2013;50(9):1542–50. doi:10.1093/rheumatology/ker192.CrossRef

17.

Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634–5. doi:10.1126/science.1071924.PubMedCrossRef

18.

Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature. 2012;492(7428):199–204. doi:10.1038/nature11700.PubMedCrossRef

19.

Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993;9:317–43. doi:10.1146/annurev.cb.09.110193.001533.PubMedCrossRef

20.

Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol. 1989;135(1):121–33.PubMedCentralPubMed

21.

Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw. 1998;9(2):145–54.PubMed

22.

Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001;33(1):19–32.PubMedCrossRef

23.

Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969–79. doi:10.1161/ATVBAHA.110.207415.PubMedCrossRef

24.

Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180(1):11–7. doi:10.1016/j.atherosclerosis.2004.11.016.PubMedCrossRef

25.

Starke RM, Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res. 2013;10(3):247–55.PubMedCentralPubMedCrossRef

26.

Chalouhi N, Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediat Inflamm. 2013;2012:271582. doi:10.1155/2012/271582.

27.

Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515–81. doi:10.1152/physrev.00024.2005.PubMedCrossRef

28.

Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013. doi:10.1038/jcbfm.2013.109.PubMed

29.

30.

Maddahi A, Kruse LS, Chen QW, Edvinsson L. The role of tumor necrosis factor-alpha and TNF-alpha receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflammation. 2011;8:107. doi:10.1186/1742-2094-8-107.PubMedCentralPubMedCrossRef

31.

Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol. 2002;22(9):1370–80.PubMedCrossRef

32.

Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16(1):19–27.PubMedCrossRef

33.

Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, Maesawa C, et al. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond). 2004;106(3):301–6. doi:10.1042/CS20030189.CrossRef

34.

Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183(4):2741–6. doi:10.4049/jimmunol.0803164.PubMedCrossRef

35.

Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23(5):376–83. doi:10.1053/euhj.2001.2805.PubMedCrossRef

36.

Edvinsson LI, Povlsen GK. Vascular plasticity in cerebrovascular disorders. J Cereb Blood Flow Metab. 2011;31(7):1554–71. doi:10.1038/jcbfm.2011.70.PubMedCentralPubMedCrossRef

37.

Treska V, Topolcan O, Pecen L. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chem Lab Med. 2000;38(11):1161–4. doi:10.1515/CCLM.2000.178.PubMedCrossRef

38.

Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997;17(11):2843–7.PubMedCrossRef

39.

Hamano K, Li TS, Takahashi M, Kobayashi T, Shirasawa B, Ito H, et al. Enhanced tumor necrosis factor-alpha expression in small sized abdominal aortic aneurysms. World J Surg. 2003;27(4):476–80. doi:10.1007/s00268-002-6690-0.PubMedCrossRef

40.

Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin YS, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57(3):558–64. discussion −64.PubMedCrossRef

41.

Jayaraman T, Paget A, Shin YS, Li X, Mayer J, Chaudhry H, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag. 2008;4(4):805–17.PubMedCentralPubMed

42.

Aoki T, Kataoka H, Ishibashi R, Nozaki K, Egashira K, Hashimoto N. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke. 2009;40(3):942–51. doi:10.1161/STROKEAHA.108.532556.PubMedCrossRef

43.

Kanematsu Y, Kanematsu M, Kurihara C, Tada Y, Tsou TL, van Rooijen N, et al. Critical roles of macrophages in the formation of intracranial aneurysm. Stroke. 2010;42(1):173–8. doi:10.1161/STROKEAHA.110.590976.PubMedCentralPubMedCrossRef

44.

Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275(2 Pt 1):E294–9.PubMed

45.

Kirwan JP, Krishnan RK, Weaver JA, Del Aguila LF, Evans WJ. Human aging is associated with altered TNF-alpha production during hyperglycemia and hyperinsulinemia. Am J Physiol Endocrinol Metab. 2001;281(6):E1137–43.PubMed

46.

Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002;23(9):1511–8.PubMedCrossRef

47.

Starke RM, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez F, Hasan DM, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. PLoS One. 2013;8(8):e71954. doi:10.1371/journal.pone.0071954.PubMedCentralPubMedCrossRef

48.

Sun SH, Tang WX, Liu C, Lin H, Yang HH. Effects of tumor necrosis factor alpha on proteolysis of respiratory muscles in rats with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30(3):186–91.PubMed

49.

Lanzke N, Kleinwachter R, Kerschischnik S, Sargsyan L, Groneberg DA, Kamradt T, et al. Differential effects of ethanol on IFN-gamma- and TNF-alpha-producing splenic T lymphocytes in a murine model of gram-negative pneumonia. Addict Biol. 2007;12(1):59–68. doi:10.1111/j.1369-1600.2006.00042.x.PubMedCrossRef

50.

Beeftink MM, Ruigrok YM, Rinkel GJ, van den Bergh WM. Relation of serum TNF-alpha and TNF-alpha genotype with delayed cerebral ischemia and outcome in subarachnoid hemorrhage. Neurocrit Care. 2011;15(3):405–9. doi:10.1007/s12028-011-9556-1.PubMedCrossRef

51.

Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004;35(10):2287–93. doi:10.1161/01.STR.0000140636.30204.da.PubMedCrossRef

52.

Nuki Y, Matsumoto MM, Tsang E, Young WL, van Rooijen N, Kurihara C, et al. Roles of macrophages in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab. 2009;29(3):495–503. doi:10.1038/jcbfm.2008.136.PubMedCentralPubMedCrossRef

53.

Hingorani A, Ascher E, Scheinman M, Yorkovich W, DePippo P, Ladoulis CT, et al. The effect of tumor necrosis factor binding protein and interleukin-1 receptor antagonist on the development of abdominal aortic aneurysms in a rat model. J Vasc Surg. 1998;28(3):522–6.PubMedCrossRef

54.

Kaneko H, Anzai T, Horiuchi K, Kohno T, Nagai T, Anzai A, et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218(2):470–8. doi:10.1016/j.atherosclerosis.2011.06.008.PubMedCrossRef

55.

Nuki Y, Tsou TL, Kurihara C, Kanematsu M, Kanematsu Y, Hashimoto T. Elastase-induced intracranial aneurysms in hypertensive mice. Hypertension. 2009;54(6):1337–44. doi:10.1161/HYPERTENSIONAHA.109.138297.PubMedCentralPubMedCrossRef

56.

Fontanella M, Rainero I, Gallone S, Rubino E, Fenoglio P, Valfre W, et al. Tumor necrosis factor-alpha gene and cerebral aneurysms. Neurosurgery. 2007;60(4):668–72. doi:10.1227/01.NEU.0000255417.93678.49. discussion 72–3.PubMedCrossRef

57.

Kondo S, Hashimoto N, Kikuchi H, Hazama F, Nagata I, Kataoka H. Apoptosis of medial smooth muscle cells in the development of saccular cerebral aneurysms in rats. Stroke. 1998;29(1):181–8. discussion 9.PubMedCrossRef

58.

Hara A, Yoshimi N, Mori H. Evidence for apoptosis in human intracranial aneurysms. Neurol Res. 1998;20(2):127–30.PubMed

59.

Jayaraman T, Marks AR. Calcineurin is downstream of the inositol 1,4,5-trisphosphate receptor in the apoptotic and cell growth pathways. J Biol Chem. 2000;275(9):6417–20.PubMedCrossRef

60.

Hanafy KA, Grobelny B, Fernandez L, Kurtz P, Connolly ES, Mayer SA, et al. Brain interstitial fluid TNF-alpha after subarachnoid hemorrhage. J Neurol Sci. 2010;291(1–2):69–73. doi:10.1016/j.jns.2009.12.023.PubMedCentralPubMedCrossRef

61.

Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72(4):337–40. doi:10.1212/01.wnl.0000341278.26993.22.PubMedCentralPubMedCrossRef

62.

Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopoulos ME, Kilidireas C, Rombos A, et al. Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013;2013:671935. doi:10.1155/2013/671935.PubMedCentralPubMed

63.

Pardo CA, Buckley A, Thurm A, Lee LC, Azhagiri A, Neville DM, et al. A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord. 2013;5(1):9. doi:10.1186/1866-1955-5-9.PubMedCentralPubMedCrossRef

64.

Wang DD, Englot DJ, Garcia PA, Lawton MT, Young WL. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav. 2012;24(3):314–8. doi:10.1016/j.yebeh.2012.03.035.PubMedCentralPubMedCrossRef

65.

Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012;26(5):391–401. doi:10.2165/11632000-000000000-00000.PubMedCrossRef

66.

Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. The prospects of minocycline in multiple sclerosis. J Neuroimmunol. 2011;235(1–2):1–8. doi:10.1016/j.jneuroim.2011.04.006.PubMedCrossRef

67.

Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets. 2010;9(3):305–13.PubMedCrossRef

68.

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1999;53(3):457–65.

69.

Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis. 2004;16(1):190–201. doi:10.1016/j.nbd.2004.01.010.PubMedCrossRef

70.

Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed. 2006;8(2):25.PubMedCentralPubMed

71.

Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482–93. doi:10.1038/nrd3030.PubMedCrossRef

Title: Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture
Authors: Robert M. Starke
Daniel M. S. Raper
Dale Ding
Nohra Chalouhi
Gary K. Owens
David M. Hasan
Ricky Medel
Aaron S. Dumont
Publication date: 01-04-2014
Publisher: Springer US
Published in: Translational Stroke Research / Issue 2/2014
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-013-0287-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tumor Necrosis Factor-α Modulates Cerebral Aneurysm Formation and Rupture

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Tenascin-C Causes Neuronal Apoptosis After Subarachnoid Hemorrhage in Rats

Aneurysm Shape Reconstruction from Biplane Angiograms in the ISUIA Collection

Translational Research Using a Mouse Model of Intracranial Aneurysm

Molecular Imaging of Cerebrovascular Lesions

Vascular Neural Network: the Importance of Vein Drainage in Stroke

Early MoCA-Assessed Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage and Relationship to 1-Year Functional Outcome